uniQure N.V. (NASDAQ:QURE) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, August 1st.
QURE has been the subject of a number of other reports. Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the company a “buy” rating in a research report on Sunday, July 23rd. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $17.00 price target on shares of uniQure N.V. in a research report on Friday, June 30th. Cowen and Company restated a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. Zacks Investment Research lowered shares of uniQure N.V. from a “buy” rating to a “sell” rating in a research report on Wednesday, May 17th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $8.00 target price on shares of uniQure N.V. in a research report on Wednesday, April 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $15.04.
uniQure N.V. (QURE) opened at 8.50 on Tuesday. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $9.72. The firm’s market cap is $216.27 million. The stock has a 50 day moving average price of $7.31 and a 200 day moving average price of $6.08.
uniQure N.V. (NASDAQ:QURE) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.05. uniQure N.V. had a negative net margin of 203.99% and a negative return on equity of 135.97%. The business had revenue of $4.94 million for the quarter, compared to the consensus estimate of $2.92 million. Equities analysts predict that uniQure N.V. will post ($3.16) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “uniQure N.V. (NASDAQ:QURE) Downgraded by ValuEngine to “Sell”” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/08/12/uniqure-n-v-nasdaqqure-downgraded-by-valuengine-updated.html.
In other news, insider Harald Petry sold 58,075 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $6.01, for a total transaction of $349,030.75. Following the completion of the transaction, the insider now directly owns 155 shares of the company’s stock, valued at $931.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 173,460 shares of company stock valued at $1,042,986. Insiders own 0.64% of the company’s stock.
Several institutional investors have recently modified their holdings of QURE. FMR LLC increased its position in shares of uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares during the period. P.A.W. Capital Corp purchased a new position in shares of uniQure N.V. during the first quarter valued at approximately $867,000. Renaissance Technologies LLC increased its position in uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after buying an additional 122,700 shares during the last quarter. Paloma Partners Management Co increased its position in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after buying an additional 74,605 shares during the last quarter. Finally, Morgan Stanley increased its position in uniQure N.V. by 14.9% in the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after buying an additional 73,418 shares during the last quarter. 30.22% of the stock is owned by hedge funds and other institutional investors.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
